St. Jude Medical (NYSE:STJ) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.71 by 21 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 18 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Brokerage firm Barclays downgrades its rating on St. Jude Medical (NYSE:STJ). As per the latest information, the brokerage house raises the price target to $80 per share from a prior target of $74. The shares have been rated Equal-weight. Previously, the analysts had a Overweight rating on the shares. The rating by the firm was issued on May 11, 2016.
St. Jude Medical (NYSE:STJ): 18 Analyst have given the stock of St. Jude Medical (NYSE:STJ) a near short term price target of $73.81. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $11.55. The higher price target estimate is at $91 while the lower price estimates are fixed at $54.
St. Jude Medical (NYSE:STJ) witnessed a decline in the market cap on Tuesday as its shares dropped 0.07% or 0.05 points. After the session commenced at $77.21, the stock reached the higher end at $77.27 while it hit a low of $76.85. With the volume soaring to 1,548,207 shares, the last trade was called at $76.85. The company has a 52-week high of $80.84. The company has a market cap of $21,847 million and there are 284,277,430 shares in outstanding. The 52-week low of the share price is $48.83.
Shares of St. Jude Medical Inc. rose by 0.05% in the last five trading days and 0.09% for the last 4 weeks. St. Jude Medical Inc. is up 40.53% in the last 3-month period. Year-to-Date the stock performance stands at 25.13%.
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).